Platelet-Like Particles from Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for platelet production are limited by the short shelf life of donor-derived platelets, contamination risks, and the challenges of large-scale production, particularly for patients with rare blood types or those requiring frequent transfusions, where conventional storage techniques cannot maintain platelet viability and safety.
Innovation Solution
The development of methods to produce platelets from human embryonic stem cells and induced pluripotent stem cells without forming embryoid bodies, under serum- and stromal-free conditions, achieving up to 100-fold expansion and generating functional platelet-like particles that can be irradiated for safety and stored for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional methods are used to store donor-derived platelets, then platelets can be stored for less than a week, but this creates continuous challenges for donor-dependent programs and shortages
Solution Approach 1:
The patent creates artificial platelet-like particles that copy the essential functions and properties of natural platelets. These synthetic particles are generated from pluripotent stem cells and can be stored indefinitely without the one-week limitation of conventional platelet storage, thereby resolving the contradiction between storage duration and supply reliability
Solution Approach 2:
The invention changes the fundamental parameters of platelet production by using pluripotent stem cells instead of donor blood, and by creating platelet-like particles rather than using intact donor platelets. This allows for indefinite storage duration while maintaining functional reliability for transfusion
2Quantity of substance
If volunteer donor programs are used to supply platelets, then platelets can be obtained from multiple donors, but there is constant risk of contamination by various pathogens
Solution Approach 1:
By creating synthetic platelet-like particles from pluripotent stem cells rather than using donor-derived platelets, the invention eliminates the pathogen contamination risk associated with volunteer donor programs while maintaining the ability to supply sufficient quantities of functional platelets
Solution Approach 2:
The patent creates disposable platelet-like particles that can be produced in large quantities from a single source (pluripotent stem cells) without the risk of pathogen transmission. These particles serve their function and are then discarded, eliminating the need for repeated donor exposure
3Productivity
If platelets are produced from human embryonic stem cells without forming embryoid bodies, then yield and purity can be greatly improved, but new culture methods must be developed
Solution Approach 1:
The invention extracts and eliminates the embryoid body formation step from the traditional differentiation pathway. By directly differentiating pluripotent stem cells into platelet-like particles without forming embryoid bodies, the method achieves higher yield and purity while simplifying the culture system
Solution Approach 2:
The patent changes the differentiation parameters by specifying particular culture conditions (serum-free, stromal cell-free) and timing that directly produce platelet-like particles without embryoid body intermediates, thereby improving productivity while managing culture system complexity
4Quantity of substance
If frequent transfusions are given to patients with rare blood types or alloimmunized patients, then platelet needs are met, but refractory responses develop linked to immunity-mediated host reaction
Solution Approach 1:
By creating patient-matched platelet-like particles from the patient's own pluripotent stem cells, the invention eliminates immune-mediated refractory responses. The synthetic particles lack the immunogenic properties of donor platelets while maintaining transfusion effectiveness, allowing repeated transfusions without developing refractory responses
Data Source
AI summary
Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.